Difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease on hemodialysis
INTRODUCTION: Chronic kidney disease-associated pruritus (CKD-aP) is often experienced by patients with CKD receiving dialysis. Approximately 40% of hemodialysis patients are 'moderately' to 'extremely bothered' by itching, associated with reduced quality of life, poor sleep quality, and depression as well as worse clinical outcomes, including increased medication use, infections, hospitalizations, and mortality.
AREAS COVERED: This review covers the pathophysiology and treatment landscape of CKD-aP, and the development, clinical efficacy, and safety profile of difelikefalin. We summarize the existing evidence, and discuss both the position of difelikefalin in the treatment pathway and potential future developments.
EXPERT OPINION: Difelikefalin is a kappa opioid receptor agonist, with a primary mode of action that is outside of the central nervous system and provides an improved safety profile compared with other opioid agonists, with limited potential for abuse and dependency. Difelikefalin has demonstrated efficacy, tolerability, and safety profile in several large-scale clinical trials in more than 1,400 hemodialysis patients with CKD-aP treated for up to 64 weeks. Difelikefalin is the only approved treatment for CKD-aP in the U.S.A and Europe; other treatments are used off-label, have limited proof of efficacy in large-scale clinical trials in this patient population, and may present an increased risk of toxicity in patients with CKD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Expert review of clinical pharmacology - 16(2023), 5 vom: 03. Mai, Seite 387-400 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rastogi, Anjay [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic kidney disease |
|---|
| Anmerkungen: |
Date Completed 18.05.2023 Date Revised 18.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/17512433.2023.2197209 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355148587 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355148587 | ||
| 003 | DE-627 | ||
| 005 | 20231226063732.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/17512433.2023.2197209 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1183.xml |
| 035 | |a (DE-627)NLM355148587 | ||
| 035 | |a (NLM)37010031 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rastogi, Anjay |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease on hemodialysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.05.2023 | ||
| 500 | |a Date Revised 18.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Chronic kidney disease-associated pruritus (CKD-aP) is often experienced by patients with CKD receiving dialysis. Approximately 40% of hemodialysis patients are 'moderately' to 'extremely bothered' by itching, associated with reduced quality of life, poor sleep quality, and depression as well as worse clinical outcomes, including increased medication use, infections, hospitalizations, and mortality | ||
| 520 | |a AREAS COVERED: This review covers the pathophysiology and treatment landscape of CKD-aP, and the development, clinical efficacy, and safety profile of difelikefalin. We summarize the existing evidence, and discuss both the position of difelikefalin in the treatment pathway and potential future developments | ||
| 520 | |a EXPERT OPINION: Difelikefalin is a kappa opioid receptor agonist, with a primary mode of action that is outside of the central nervous system and provides an improved safety profile compared with other opioid agonists, with limited potential for abuse and dependency. Difelikefalin has demonstrated efficacy, tolerability, and safety profile in several large-scale clinical trials in more than 1,400 hemodialysis patients with CKD-aP treated for up to 64 weeks. Difelikefalin is the only approved treatment for CKD-aP in the U.S.A and Europe; other treatments are used off-label, have limited proof of efficacy in large-scale clinical trials in this patient population, and may present an increased risk of toxicity in patients with CKD | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chronic kidney disease | |
| 650 | 4 | |a chronic kidney disease-associated pruritus | |
| 650 | 4 | |a difelikefalin | |
| 650 | 4 | |a efficacy | |
| 650 | 4 | |a kappa opioid receptor | |
| 650 | 4 | |a opioids | |
| 650 | 4 | |a pruritus | |
| 650 | 4 | |a safety | |
| 650 | 7 | |a difelikefalin |2 NLM | |
| 650 | 7 | |a NA1U919MRO |2 NLM | |
| 700 | 1 | |a Fishbane, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Lerma, Edgar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of clinical pharmacology |d 2008 |g 16(2023), 5 vom: 03. Mai, Seite 387-400 |w (DE-627)NLM192063413 |x 1751-2441 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2023 |g number:5 |g day:03 |g month:05 |g pages:387-400 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/17512433.2023.2197209 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2023 |e 5 |b 03 |c 05 |h 387-400 | ||